Skip to content
10-K/A

Annual Report

MABVAX THERAPEUTICS HOLDINGS, INC.

0001654954-18-011102

← back to feed
Filed
Oct 15, 2018 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2017 · Apr 2, 2018 8.96M sh
Capex FY 2017 · Dec 31, 2017 $21.07K
Capex FY 2017 · Dec 31, 2016 $563.2K
Operating Cash Flow FY 2017 · Dec 31, 2017 $11M
Long Term Debt FY 2017 · Dec 31, 2017 $3.63M
Cash And Equivalents FY 2017 · Dec 31, 2017 $885.71K
Cash And Equivalents FY 2017 · Dec 31, 2016 $3.98M
Cash And Equivalents FY 2017 · Dec 31, 2015 $4.08M
Stockholders Equity FY 2017 · Dec 31, 2017 $1.13M
Stockholders Equity FY 2017 · Dec 31, 2016 $3.34M
Stockholders Equity FY 2017 · Dec 31, 2015 $7.44M
Current Liabilities FY 2017 · Dec 31, 2017 $5.81M
Current Liabilities FY 2017 · Dec 31, 2016 $5.69M
Total Liabilities FY 2017 · Dec 31, 2017 $7.66M
Total Liabilities FY 2017 · Dec 31, 2016 $8.68M
Current Assets FY 2017 · Dec 31, 2017 $1.21M
Current Assets FY 2017 · Dec 31, 2016 $4.29M
Total Assets FY 2017 · Dec 31, 2017 $8.79M
Total Assets FY 2017 · Dec 31, 2016 $12.02M
Sga Expense FY 2017 · Dec 31, 2017 $10.53M
Sga Expense FY 2017 · Dec 31, 2016 $9.01M
Rd Expense FY 2017 · Dec 31, 2017 $7.54M
Rd Expense FY 2017 · Dec 31, 2016 $7.8M
Net Income FY 2017 · Dec 31, 2017 −$19.02M
Net Income FY 2017 · Dec 31, 2016 −$17.66M
Operating Income FY 2017 · Dec 31, 2017 −$18.07M
Operating Income FY 2017 · Dec 31, 2016 −$16.66M
Revenue FY 2017 · Dec 31, 2017 $0
Revenue FY 2017 · Dec 31, 2016 $148.05K